TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics to Present at Upcoming Investor Conferences

08 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

09 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

15 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

09 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2022 Financial Results

27 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

26 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2022 Financial Results

20 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

13 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 Aug 2022 06:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 Jul 2022 15:30:00 By Nasdaq GlobeNewswire